Menu Search
Equities

Alkermes Plc

ALKS:NSQ

Alkermes Plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.35
  • Today's Change0.52 / 1.87%
  • Shares traded1.13m
  • 1 Year change-5.22%
  • Beta0.4275
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alkermes Plc grew revenues 49.61% from 1.11bn to 1.66bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 158.27m to a profit of 355.76m.
Gross margin83.31%
Net profit margin30.34%
Operating margin24.91%
Return on assets20.83%
Return on equity35.68%
Return on investment26.98%
More ▼

Cash flow in USDView more

In 2023, Alkermes Plc increased its cash reserves by 56.41%, or 165.00m. The company earned 401.35m from its operations for a Cash Flow Margin of 24.13%. In addition the company generated 53.36m cash from investing, though they paid out 289.71m more in financing than they received.
Cash flow per share2.97
Price/Cash flow per share9.00
Book value per share7.74
Tangible book value per share7.23
More ▼

Balance sheet in USDView more

Alkermes Plc has a Debt to Total Capital ratio of 18.40%, a lower figure than the previous year's 22.57%.
Current ratio2.99
Quick ratio2.61
Total debt/total equity0.2254
Total debt/total capital0.184
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.